Vertex Pharmaceuticals Incorporated (ETR:VX1)
Germany
· Delayed Price · Currency is EUR | Market Cap | 113.54B |
| Revenue (ttm) | 10.64B |
| Net Income (ttm) | -517.34M |
| Shares Out | n/a |
| EPS (ttm) | -2.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 19 |
| Average Volume | 193 |
| Open | 446.65 |
| Previous Close | 440.10 |
| Day's Range | 443.15 - 447.00 |
| 52-Week Range | 362.70 - 489.20 |
| Beta | 0.46 |
| RSI | 53.92 |
| Earnings Date | May 5, 2025 |
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The com... [Read more]
News
Final Trades: Berkshire Hathaway, Vertex Pharma, S&P Global and CME Group
Final Trades are in! The Investment Committee reveals their top picks to close out the day—don't miss it!
Final Trades: Berkshire Hathaway, Vertex Pharma, S&P Global and CME Group
Final Trades are in! The Investment Committee reveals their top picks to close out the daydont miss it!
Baron Health Care Fund Q1 2025 Top Net Purchases And Sales
Initiated positions in Waters Corporation, Penumbra, McKesson, Masimo, and added to UnitedHealth Group due to strong market positions and growth potential. Waters Corporation's growth driven by biopha...
Baron Health Care Fund Q1 2025 Top Contributors And Detractors
Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals sa...
Biomay Obtains FDA Approval for Manufacturing of Cas9 Nuclease at Headquarters Site (FOTO)
Vienna (ots) - The company announced its successful approval by the U.S. Food and Drug Administration (FDA) for the manufacturing, testing and release of recombinant Cas9 nuclease from its headquarter...
We're in a pharma stock pickers market, says Kessef's Len Yaffe
Len Yaffe, Kessef Capital Management, joins 'Fast Money' to talk opportunities in the pharma stock space.
Why Vertex Pharmaceuticals Was Such a Healthy Stock on Tuesday
Eli Lilly, Vertex, AbbVie and More Pharma Stocks to Own as Tariffs Loom
Trump's tariff policy is the latest uncertainty to plague the pharmaceutical sector.
Vertex Has A Lot Riding On Alyftrek, Journavx — And Investors Are Watching Closely
Vertex Pharmaceuticals Inc VRTX is entering earnings week with some serious anticipation — and a bit of heartburn. The stock had a solid run in 2025, up nearly 20% year-to-date and 21% over the past 1...
Vertex Has A Lot Riding On Alyftrek, Journavx — And Investors Are Watching Closely
Vertex Pharmaceuticals Inc (NASDAQ: VRTX) is entering earnings week with some serious anticipation — and a bit of heartburn. The stock had a solid run in 2025, up nearly 20% year-to-date and 21% over...
Peering Into Vertex Pharmaceuticals's Recent Short Interest
Vertex Pharmaceuticals's (NYSE: VRTX) short percent of float has fallen 22.32% since its last report. The company recently reported that it has 4.46 million shares sold short , which is 1.74% of all ...
Mumbai-Born US CEO Reshma Kewalramani Named In TIME's 2025 Influential List
Reshma Kewalramani, the Indian-origin CEO of US-based Vertex Pharmaceuticals, has been named on the list of "100 Most Influential People" of 2025 by Time Magazine.
Vertex Pharmaceuticals (VRTX) Celebrated for Groundbreaking CF Research
Vertex Pharmaceuticals (VRTX) Celebrated for Groundbreaking CF Research
CrowdStrike, Robinhood, Palo Alto Networks And A Health Care Stock On CNBC's 'Final Trades'
On CNBC's “Halftime Report Final Trades ,” Joshua Brown of Ritholtz Wealth Management picked CrowdStrike Holdings, Inc . (NASDAQ: CRWD). On Wednesday, CrowdStrike announced an expansion of its partne...
Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Paul Negulescu, Ph.D. Senior Vice President, Vertex has been awarded the 2025 Canada Gairdner Internati...
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
Final Trades: Vertex, Robinhood, Palo Alto and Crowdstrike
The Investment Committee give you their top stocks to watch in this volatile markets.
GreensKeeper Q1 2025 Portfolio Update
Berkshire Hathaway led Q1 with a 17.5% return, driven by strong operating earnings and potential for significant acquisitions with over $300 billion in cash. Vertex Pharmaceuticals gained 20.4%, fuele...
Is Vertex Pharmaceuticals Stock a Buy?
European Commission Expands Approval for Vertex's Kaftrio (VRTX)
European Commission Expands Approval for Vertex's Kaftrio (VRTX)
Vertex to Announce First Quarter 2025 Financial Results on May 5th
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2025 financial results on Monday, May 5, 2025 after the financial markets close. The company w...
Vertex Pharmaceuticals gets EU nod to expand label for cystic fibrosis treatment
Vertex's Journavx Launch Sparks Optimism, Analyst Sees 'Two Potential Upside Levers'
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) is giving investors some good news — especially if they're keeping a close eye on its newly launched painkiller Journavx . Journavx Gains Early Traction At ...
Vertex's Journavx Launch Sparks Optimism, Analyst Sees 'Two Potential Upside Levers'
Vertex Pharmaceuticals Inc. VRTX is giving investors some good news — especially if they're keeping a close eye on its newly launched painkiller Journavx.
European Commission Approves Expanded Label for KAFTRIO in Combination With Ivacaftor for People With Cystic Fibrosis
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted regulatory approval for a label expansion of KAFTRIO (ivacaftor/tezacaftor/elexacaftor) in a combination ...